Granted Patent
B2
US 12,263,253 · App. 18/816,200 · Granted Apr 1, 2025
Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
Inventors:
Chase Spenser Coffman (Newton, MA); Lyndon Fitzgerald Charles, Jr. (Medford, MA); Paul Brown (Boston, MA); Daniel Benjamin Dadon (East Boston, MA); Lisa Liu (Somerville, MA); Sadiqua Shadbar (Allston, MA); Chaitanya Sudrik (Stoneham, MA)
Assignee:
Elektrofi, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention provides particles, compositions including the particles, and methods of making the particles using electrospray. In certain embodiments, the particles allow for high concentrations of a therapeutic or diagnostic agent to be delivered at low viscosity. Particles may also exhibit beneficial properties with respect to stability.
Claims (20)
1. A composition comprising dehydrated particles, wherein the particles: comprise a protein having 0.5 to 1.0 activity per unit, are suspended in a non-aqueous liquid, and have less than 10% aggregation of the protein.
2. The composition of claim 1 , wherein the particles comprise less than 10% fragmentation of the protein.
3. The composition of claim 1 , wherein the particles have less than a 50% change in charge variants of the protein compared to the protein prior to dehydration.
4. The composition of claim 1 , wherein the suspension further comprises insoluble particulate matter larger than or equal to 1 μm.
5. The composition of claim 4 , wherein the number of insoluble particles is from 0 to 100,000,000 per mL.
6. The composition of claim 4 , wherein the number of insoluble particles greater than 10 μm is from 0 to 6,000 per mL.
7. The composition of claim 4 , wherein the number of insoluble particles greater than 25 μm is from 0 to 600 per mL.
8. The composition of claim 1 , wherein the particles have a diameter from 0.1 to 1000 μm.
9. The composition of claim 1 , wherein the particles have a polydispersity index from 0.05 to 0.9.
10. The composition of claim 1 , wherein the concentration of the protein in an aqueous first liquid before dehydration of the particles is from 0.0001 to 1000 mg/mL.
11. The composition of claim 1 , wherein the particles are dehydrated from an aqueous first liquid selected from the group consisting of water, 0.9% saline, lactated Ringer's solution, dextrose 5%, or a buffer.
12. The composition of claim 1 , wherein the particles are dehydrated from an aqueous first liquid comprising a carbohydrate, a pH adjusting agent, a salt, a chelator, a mineral, a polymer, a surfactant, a protein stabilizer, an emulsifier, an antiseptic, an amino acid, an antioxidant, a protein, an organic solvent, a paraben, a bactericide, a fungicide, a vitamin, a preservative, or a nutrient media.
13. The composition of claim 1 , wherein the non-aqueous liquid is an organic solvent.
14. The composition of claim 13 , wherein the organic solvent is selected from the group consisting of benzyl benzoate, coconut oil, cottonseed oil, fish oil, grape seed oil, hazelnut oil, hydrogenated vegetable oils, olive oil, palm seed oil, peanut oil, peppermint oil, safflower oil, sesame oil, soybean oil, sunflower oil, walnut oil, acetone, ethyl acetate, ethyl lactate, dimethylacetamide, dimethyl isosorbide, dimethyl sulfoxide, glycofurol, diglyme, methyl tert-butyl ether, N-methyl pyrrolidone, perfluorodecalin, polyethylene glycol, 2-pyrrolidone, tetrahydrofurfuryl alcohol, trigylcerides, triglycerides of the fractionated plant fatty acids C8 and C10, propylene glycol diesters of saturated plant fatty acids C8 and C10, ethyl oleate, ethyl caprate, dibutyl adipate, fatty acid esters, hexanoic acid, octanoic acid, triacetin, diethyl glycol monoether, gamma-butyrolactone, eugenol, clove bud oil, citral, and limonene or any combination thereof.
15. The composition of claim 13 , wherein the organic solvent is selected from the group consisting of polyoxyl 40 hydrogenated castor oil, polyoxyl 35 castor oil, a simple alcohol, gamma-butyrolactone, tocopherol, octa-fluoropropane, (perfluorohexyl) octane, n-acetyltryptophan, ethyl laurate, methyl caprylate, methyl caprate, methyl myristate, methyl oleate, methyl linoleate, dimethyl adipate, dibutyl suberate, diethyl sebacate, ethyl macadamiate, trimethylolpropane triisosterate, isopropyl laurate, isopropyl myristate, diethyl succinate, polysorbate esters, ethanol amine, propanoic acid, citral, anisole, anethol, benzaldehyde, linalool, caprolactone, phenol, thioglycerol, dimethylacetamide, diethylene glycol monoethyl ether, solketal, isosorbide dimethyl ether, ethyl formate, and ethyl hexyl acetate.
16. The composition of claim 1 , wherein the composition has a viscosity from 0.27 to 200 cP.
17. The composition of claim 1 , wherein the composition comprises from 5 to 90% particles by volume.
18. The composition of claim 1 , wherein the composition has a concentration of the protein from 0.0001 to 1000 mg/mL.
19. The composition of claim 1 , wherein the protein is selected from the group consisting of antibodies or fragments thereof, nucleoproteins, glycoproteins, lipoproteins, and any combination thereof.
20. The composition of claim 15 , wherein the simple alcohol comprises ethanol, octanol, hexanol, decanol, propanol, butanol, or a combination thereof.
Assignments (2)
CHANGE OF NAME
Recorded Feb 2, 2026
From: ELEKTROFI, INC.
To: HALOZYME HYPERCON, INC.
Reel/Frame 073662/0717 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 27, 2024
From: COFFMAN, CHASE; CHARLES, LYNDON; BROWN, PAUL; DADON, DANIEL BENJAMIN; LIU, LISA; SHADBAR, SADIQUA; SUDRIK, CHAITANYA
To: ELEKTROFI, INC.
Reel/Frame 068720/0877 →
Continuity (3)
Continuation
17058339
Provisional Application
62676169
· May 24, 2018
References Cited (197)
US 3013007A
· Dale et al.
· 1961
[cited by applicant]
US 3882036A
· Krezanoski et al.
· 1975
[cited by applicant]
US 4172896A
· Uno et al.
· 1979
[cited by applicant]
US 4531056A
· Labowsky et al.
· 1985
[cited by applicant]
US 5358970A
· Ruff et al.
· 1994
[cited by applicant]
US 5427798A
· Ludwig et al.
· 1995
[cited by applicant]
US 5541231A
· Ruff et al.
· 1996
[cited by applicant]
US 5595721A
· Kaminski et al.
· 1997
[cited by applicant]
US 5612055A
· Bedford et al.
· 1997
[cited by applicant]
US 5677180A
· Robinson et al.
· 1997
[cited by applicant]
US 5731000A
· Ruff et al.
· 1998
[cited by applicant]
US 5736137A
· Anderson et al.
· 1998
[cited by applicant]
US 5763493A
· Ruff et al.
· 1998
[cited by applicant]
US 5840731A
· Mayer et al.
· 1998
[cited by applicant]
US 6095134A
· Sievers et al.
· 2000
[cited by applicant]
US 6110973A
· Young
· 2000
[cited by applicant]
US 8013022B2
· Deangelo et al.
· 2011
[cited by applicant]
US 8512754B2
· Needham
· 2013
[cited by applicant]
US 8728525B2
· Brown et al.
· 2014
[cited by applicant]
US 8779094B2
· Johnston et al.
· 2014
[cited by applicant]
US 8939388B1
· Beetz et al.
· 2015
[cited by applicant]
US 9259701B2
· Palmer et al.
· 2016
[cited by applicant]
US 9364542B2
· Chang
· 2016
[cited by applicant]
US 9643996B2
· Petrel et al.
· 2017
[cited by applicant]
US 20020081732A1
· Bowlin et al.
· 2002
[cited by applicant]
US 20030055010A1
· De Haan
· 2003
[cited by applicant]
US 20050186183A1
· Deangelo et al.
· 2005
[cited by applicant]
US 20060147400A1
· Piot
· 2006
[cited by applicant]
US 20080026068A1
· Brown
· 2008
[cited by examiner]
US 20090035381A1
· Stankus et al.
· 2009
[cited by applicant]
US 20100092526A1
· Baker, Jr. et al.
· 2010
[cited by applicant]
US 20100330169A1
· Bunick et al.
· 2010
[cited by applicant]
US 20120244196A1
· Okubo et al.
· 2012
[cited by applicant]
US 20140052020A1
· Allen et al.
· 2014
[cited by applicant]
US 20140262694A1
· Knigge
· 2014
[cited by applicant]
US 20140308270A1
· Lobo et al.
· 2014
[cited by applicant]
US 20140348852A1
· Vos et al.
· 2014
[cited by applicant]
US 20140378370A1
· Johnston et al.
· 2014
[cited by applicant]
US 20160128944A1
· Chawrai et al.
· 2016
[cited by applicant]
US 20160250329A1
· Bukrinski et al.
· 2016
[cited by applicant]
US 20220211627A1
· Arrighi et al.
· 2022
[cited by applicant]
US 20230065628A1
· Auer et al.
· 2023
[cited by applicant]
US 20230094393A1
· Charles et al.
· 2023
[cited by applicant]
US 20230338299A1
· Paul et al.
· 2023
[cited by applicant]
US 20240255517A1
· Carter et al.
· 2024
[cited by applicant]
US 20240270864A1
· Brown et al.
· 2024
[cited by applicant]
CN 1750811A
· 2006
[cited by applicant]
EP 0677332A2
· 1995
[cited by applicant]
EP 2773330B1
· 2020
[cited by applicant]
JP 2008266128A
· 2008
[cited by applicant]
JP 2010524948A
· 2010
[cited by applicant]
JP 2011079747A
· 2011
[cited by applicant]
JP 2013166100A
· 2013
[cited by applicant]
JP 2014058466A
· 2014
[cited by applicant]
JP 2014129357A
· 2014
[cited by applicant]
WO 9911196A1
· 1999
[cited by applicant]
WO 0335301A1
· 2003
[cited by applicant]
WO 2006087354A2
· 2006
[cited by applicant]
WO 2007059782A1
· 2007
[cited by applicant]
WO 2008062908A1
· 2008
[cited by applicant]
WO 2008092084A2
· 2008
[cited by applicant]
WO 2010044867A1
· 2010
[cited by applicant]
WO 2010082543A1
· 2010
[cited by applicant]
WO 2011131943A2
· 2011
[cited by applicant]
WO 2012042274A1
· 2012
[cited by applicant]
WO 2014057424A2
· 2014
[cited by applicant]
WO 2015085898A1
· 2015
[cited by applicant]
WO 2015138844A1
· 2015
[cited by applicant]
WO 2015196091A1
· 2015
[cited by applicant]
WO 2016014497A1
· 2016
[cited by applicant]
WO 2016089309A1
· 2016
[cited by applicant]
WO 2017106716A1
· 2017
[cited by applicant]
WO 2018098376A1
· 2018
[cited by applicant]
WO 2019023392A1
· 2019
[cited by applicant]
WO 2019226969A1
· 2019
[cited by applicant]
WO 2020051307A1
· 2020
[cited by applicant]
WO 2020160323A2
· 2020
[cited by applicant]
WO 2021050953A1
· 2021
[cited by applicant]
WO 2021158959A2
· 2021
[cited by applicant]
WO 2021168271A1
· 2021
[cited by applicant]
WO 2021212019A1
· 2021
[cited by applicant]
WO 2022256840A2
· 2022
[cited by applicant]
WO 2023212721A1
· 2023
[cited by applicant]
Morales-Cruz et al., “Two-step nanoprecipitation for the production of protein-loaded PLGA nanospheres,” Results Pharma Sci. 2: 79-85 (2012).
[cited by applicant]
Mueller et al., “The rheology of suspensions of solid particles,” Proc R Soc A. 466: 1201-1228 (2010).
[cited by applicant]
Naqvi et al., “Living cell factories—electrosprayed microcapsules and microcarriers for minimally invasive delivery,” Adv Maler. 28(27): 5662-71 (2016)(10 pages).
[cited by applicant]
Nema et al., Pharmaceutical Dosage Forms: Parenteral Medications, Third Edition, vol. 3: Requlations, Validation and the Future. Informa Healthcare, vii-304 (2010) (328 pages).
[cited by applicant]
Nguyen et al., “Pharmaceutical applications of electrospraying,” J Pharm Sci. 105(9): 2601-2620 (2016).
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/058,339, mailed Jul. 29, 2024.
[cited by applicant]
Park et al., “One step immobilization of protein encapsulated core/shell particles onto nanofibers,” Macromol Maler Eng. 295(6): 544-550 (2010).
[cited by applicant]
Patel et al., “Poloxamers: a pharmaceutical excipients with therapeutic behaviors,” International Journal of PharmTech Research. 1(2):299-303 (2009).
[cited by applicant]
Persic, L. et al., “An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries,” Gene; 9-18 (1997).
[cited by applicant]
Pivnik, A.V., “Use of rituximab for treatment of HIV-infected patients with hematological disorders,” Genotekhnologiya Medical Center, Moscow, 7 pages; English Abstract Only (2013).
[cited by applicant]
Press, O.W. et al., “Monoclonal Antibody 1F5 (Anti-CD20) Serotherapy of Human B Cell Lymphoma,” Blood, vol. 69; No. 2; 584-591 (1987).
[cited by applicant]
Reichardt, C., “Solvatochromic Dyes as Solvent Polarity Indicators,” Chem. Rev., vol. 94; 2319-2358 (1994).
[cited by applicant]
Richardson, H. et al., “Influence of the glass transition on solvent loss from spin-cast glassy polymer thin films,” Eur. Phys. J. E, vol. 12; 021; S87-S91 (2003).
[cited by applicant]
Saglam et al., “Preparation of high protein micro-particles using two-step emulsification,” Food Hydrocolloids. 25(5):1139-48 (2011).
[cited by applicant]
Sblattero, D. and Bradbury, A., “Exploiting recombination in single bacteria to make large phage antibody libraries,” Nature Biotechnology, vol. 18; 75-80 (2000).
[cited by applicant]
Serra-Peinado, C., et al., “Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab,” Nature Communications, vol. 10; 15 pages (2019).
[cited by applicant]
Shire et al., “Challenges in the development of high protein concentration formulations,” J Pharm Sci. 93(6): 1390-402 (2004).
[cited by applicant]
Supplementary Partial European Search Report for European Patent Application No. 17873547.8, dated Jun. 15, 2020 (9 pages).
[cited by applicant]
Takats et al., “Electrosonic spray ionization. A gentle technique for generating folded proteins and protein complexes in the gas phase and for studying ion-molecule reactions at atmospheric pressure,” Anal Chem. 76(14)…
[cited by applicant]
Torchilin, “Multifunctional nanocarriers,” Adv Drug Deliv Rev. 58(14): 1532-55 (2006).
[cited by applicant]
U.S. Department of Health and Human Services, “Q3C—Tables and List: Guidance for Industry,” Aug. 2018 (10 pages).
[cited by applicant]
Vanhoff, Sebastian, Thesis: “The Influence of Atomization Conditions on Protein Secondary and Tertiary Structure During Microparticle Formation by Spray-Freezing-Drying ,” Doktorgrades Dr. rer. nat, Der Naturwissenschaf…
[cited by applicant]
Vehring, “Pharmaceutical particle engineering via spray drying,” Pharm Res. 25(5): 999-1022 (2008).
[cited by applicant]
Wang et al., “FDA's regulatory science program for generic PLA/ PLGA-based drug products,” Am Pharm Rev. <https://www.americanpharmaceuticalreview.com/Featured-Articles/188841-FDA-s- Regulatory-Science-Program-for-Gener…
[cited by applicant]
Wanning et al., “Pharmaceutical spray freeze drying,” Int J Pharm. 488(1-2): 136-53 (2015).
[cited by applicant]
Xie et al., “Encapsulation of protein drugs in biodegradable microparticles by co-axial electrospray,” J Colloid Interface Sci. 317(2): 469-76 (2008).
[cited by applicant]
Yuan et al., “Coaxial electrospray of curcumin-loaded microparticles for sustained drug release,” PLoS One. 10(7): e0132609 (2015) (15 pages).
[cited by applicant]
Yuan et al., “One-step fabrication of triple-layered microcapsules by a tri-axial flow focusing device for microencapsulation of soluble drugs and imaging agents,” Proc SPIE vol. 9711, Imaging, Manipulation, and Analysi…
[cited by applicant]
Zhang et al., “Coaxial electrospray of microparticles and nanoparticles for biomedical applications,” Expert Rev Med Devices. 9(6): 595-612 (2012).
[cited by applicant]
Zhang et al., “Coaxial electrospray of ranibizumab-loaded microparticles for sustained release of anti-VEGF therapies,” PloS One. 10(8):e0135608 (2015) (16 pages).
[cited by applicant]
Zhiqi, L., et al., “Functional Emulsifiers and Emulsions”, China Light Industry Press, Apr. 30, 2000, 2 pages. (Concise explanation met by Translation of Search report being cited as Other Document 10 in IDS being cited…
[cited by applicant]
Zliabicki et al., “Crystal nucleation in an electric field,” Macromol Symp. 104(1): 65-87 (1996).
[cited by applicant]
Allahham, D. et al., “Development and application of a micro-capillary rheometer for in-vitro evaluation of parenteral injectability,” Journal of Pharmacy and Pharmacology, vol. 56; 709-716 (2004).
[cited by applicant]
Aniket et al., “Microglassification TM: A novel technique for protein dehydration,” J Pharm Sci. 103(3): 810-820 (2014).
[cited by applicant]
Banerjee et al., “Electrospray ionization mass spectrometry: a technique to access the information beyond the molecular weight of the analyte,” Int J Anal Chem. Article 282574 (2012) (40 pages).
[cited by applicant]
Bock et al., “ Electrospraying of polymers with therapeutic molecules: state of the art,” Prog Polym Sci. 37(11): 1510-1551 (2012) (67 pages).
[cited by applicant]
Bogelein et al., “Cyclone selection influences protein damage during drying in a mini spray-dryer,” Int J Pharm. 401(1-2): 68-71 (2010).
[cited by applicant]
Capelle, M.A.H. et al., “High throughout screening of protein formulation stability: Practical considerations,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 65; 131-148 (2007).
[cited by applicant]
Clackson, T. et al., “Making antibody fragments using phage display libraries,” Nature vol. 352; 624-628 (1991).
[cited by applicant]
Cloupeau et al., “Electrostatic spraying of liquids: Main functioning modes,” J Electrostat. 25(2): 165-184 (1990).
[cited by applicant]
Cloupeau et al., “Electrohydrodynamic spraying functioning modes: a critical review,” J Aerosol Sci. 25(6): 1021-1036 (1994).
[cited by applicant]
CN Search report Mailed on Jan. 13, 2024 for CN Application No. 2021800293477 (with English Translation).
[cited by applicant]
CN Search report Mailed on Jul. 28, 2022 for CN Application No. 202080012222.9 (With English Translation).
[cited by applicant]
Dias et al., “Tolerability of High-vol. Subcutaneous Injections ofa Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects,” AAPS PharmSciTech. 16(5): 1101-1107 (2015).
[cited by applicant]
Elektrofi, Inc., Redefining the Delivery of Biologics, 11 pages, retrieved from Internet URL: https://www.elektrofi.com/welcome#technology on Nov. 15, 2021.
[cited by applicant]
English Translation of CN Office Action Mailed on Aug. 3, 2022 for CN Application No. 202080012222.9, 4 pages.
[cited by applicant]
English translation of Office Action issued in Chinese Patent Application No. 201780072350.0, issued May 17, 2021 (16 pages).
[cited by applicant]
European Search Report and Search Opinion Received for EP Application No. 18838118, mailed on May 6, 2021, 12 pages.
[cited by applicant]
Fenn et al., “Electrospray ionization for mass spectrometry of large biomolecules,” Science. 246(4926):64-71 (Oct. 6, 1989).
[cited by applicant]
Fernandez de la Mora et al., “The current emitted by highly conducting taylor cones,” J Fluid Mech. 260: 155-184 (1994).
[cited by applicant]
Fernandez de la Mora et al., “The fluid dynamics of Taylor cones,” Annu Rev Fluid Mech. 39: 217-43 (2007) (29 pages).
[cited by applicant]
Forgacs, E. et al., “Direct (Normal)-Phase High-Performance Liquid Chromatography,” Chapter II.B. in Molecular Basis of Chromatographic Separation, CRC Press, Baco Raton, FL; 120-131 (1997).
[cited by applicant]
Galam et al., “High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase,” available in PMC Mar. 1, 2008, published in final edited form as: Bioorg Med Che…
[cited by applicant]
Ganan-Calvo et al., “Current and droplet size in the electrospraying ofliquids. Scaling laws,” J Aerosol Sci. 28(2): 249-275 (1997).
[cited by applicant]
Gapinski et al., “Structure and dimensions of core-shell nanoparticles comparable to the confocal volume studied by means of fluorescence correlation spectroscopy,” Langmuir. 32(10): 2482-2491 (Feb. 2016).
[cited by applicant]
Gikanga et al.,“ Manufacturing of High-Concentration Monoclonal Antibody Formulations via Spray Drying-the Road to Manufacturing Scale,” PDA J Pharm Sci Technol. 69(1): 59-73 (2015) (16 pages).
[cited by applicant]
Giugliano et al., “Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a ra…
[cited by applicant]
Haggag et al., “Evaluation of nano spray drying as a method for drying and formulation of therapeutic peptides and proteins,” Front Pharmacol. 6:140 (2015) (5 pages).
[cited by applicant]
Hickey, J.W. et al., “Biologically Inspired Design ofNanoparticle Artificial Antigen-Presenting Cells for Immunomodulation,” Nano Letters, vol. 17; 7045-7054 )2017).
[cited by applicant]
Hui et al., “Progress in preparation of peptide protein drug microspheres,” The medicine herald, Issue 10, 2007, pp. 1-32. (Concise explanation met by English Translation of Search report cited concurrently as Other Doc…
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/033875, mailed Oct. 21, 2019 (15 pages).
[cited by applicant]
Invitation to Pay Additional Fee received for PCT Patent Application No. PCT/US19/33875, mailed on Jul. 29, 2019, 3 pages.
[cited by applicant]
Janssen Biotech Inc., “Highlights of prescribing information,” <http://www.janssenlabels.com/package-inserl/product-monograph/prescribinginformation/DARZALEX-pi.pdl>, dated Jul. 2019, retrieved on Aug. 22, 2019 (13 page…
[cited by applicant]
Jones, A.J.S., “Analysis of Polypeptides and Proteins,” Advanced Drug Delivery Reviews, vol. 10; 29-90 (1993).
[cited by applicant]
Kaltashov et al., “Electrospray ionization mass spectrometry can provide estimates of protein surface areas in solution,”available in PMC Jan. 27, 2009, published in final edited form as: Anal Chem. 77(16): 5370-5379 (2…
[cited by applicant]
Kaltashov et al., “Estimates of Protein Surface Areas in Solution by Electrospray Ionization Mass Spectrometry,” available in PMC Jan. 27, 2009, published in final edited form as: Anal Chem. 77(16): 5370-5379 (2005) (21…
[cited by applicant]
Kim et al., “Controlled production of emulsion drops using an electric field in a flow-focusing microfluidic device,” Appl Phys Lett. 91: 133106 (2007) (3 Pages).
[cited by applicant]
Ku et al., “Electrospray characteristics of highly viscous liquids,” J Aerosol Sci. 33(10): 1361-1378 (2002).
[cited by applicant]
Lal et al., “Clean western blot signals from immunoprecipitated samples,” available in PMC Jan. 25, 2006, published in final edited form as: Mol Cell Probes. 19(6): 385-388 (2005) (5 pages).
[cited by applicant]
Lavorini et al., “New inhaler devices—the good, the bad and the ugly,” Respiration. 88(1): 3-15 (2014).
[cited by applicant]
Lee et al., “Solid-state stabilization of a Chymotrypsin and catalase with carbohydrates,” Ind Eng Chem Res. 45(14): 5134-5147 (2006).
[cited by applicant]
Lee, Spray-Drying of Proteins. Rational Design of Stable Protein Formulations. Carpenter and Manning, 135-158 (2002).
[cited by applicant]
Li et al., “Effects of pulsed electric fields and heat treatment on stability and secondary structure of bovine immunoglobulin G,” J Agric Food Chem. 53(3): 663-670 (2005).
[cited by applicant]
Longman et al., “Identifying differences in solution Conformations of two chimeric IgG3 antibodies through triple detection SEC,” LCGC North America. 18(21): (2005) (10 pages).
[cited by applicant]
Lopez-Herrera et al., “Coaxial jets generated from eleclified Taylor cones. Scaling laws,” J Aerosol Sci. 34(5): 535-552 (2003).
[cited by applicant]
Loscertales et al., “Micro/nano encapsulation via electrified coaxial liquid jets,” Science. 295(5560): 1695-8 (2002).
[cited by applicant]
Makadia et al., “Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier,” Polymers (Basel). 3(3): 1377-1397 (2011).
[cited by applicant]
Mardles. E. W. J., “Viscosity of Suspensions and the Einstein Equation,” Nature. 145: 970 (Jun. 22, 1940).
[cited by applicant]
Marks, J.D. et al., “By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage,” J. Mol. Biol., vol. 222; 581-597 (1991).
[cited by applicant]
Miller et al., “ Antibody nanoparticle dispersions formed with mixtures of crowding molecules retain activity and in vivo bioavailability,” available in PMC Oct. 1, 2013, published in final edited form as: J Pharm Sci. …
[cited by applicant]
Miller et al., “Low viscosity highly concentrated injectable nonaqueous suspensions of lysozyme microparticles,” available in PMC Feb. 17, 2011, published in final edited form as: Langmuir. 26(2): 1067-1074 (2010) (22 p…
[cited by applicant]
Moghadam et al., “Electro-spray of high viscous liquids for producing mono-sized spherical alginate beads,” Particuology. 6(4): 271-275 (2008).
[cited by applicant]
Cited By (4)